{"nctId":"NCT02074514","briefTitle":"Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection","startDateStruct":{"date":"2014-03"},"conditions":["Chronic HCV Infection"],"count":117,"armGroups":[{"label":"Sofosbuvir+RBV 16 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: Sofosbuvir","Drug: RBV"]},{"label":"Sofosbuvir+RBV 24 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: Sofosbuvir","Drug: RBV"]}],"interventions":[{"name":"Sofosbuvir","otherNames":["Sovaldi®","GS-7977","PSI-7977"]},{"name":"RBV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* HCV RNA ≥10\\^4 IU/mL at screening\n* Confirmed chronic HCV genotype 1 or 3 infection\n* HCV treatment naive\n* Approximately 30% of individuals may have compensated cirrhosis at screening\n\nExclusion Criteria:\n\n* Any other chronic liver disease\n* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)\n* Current or prior history of clinical hepatic de-compensation\n* Contraindication to RBV therapy, e.g., history of clinically significant hemoglobinopathy (sickle cell disease, thalassemia).\n* Chronic use of systemically administered immunosuppressive agents\n* History of solid organ transplantation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) 12 weeks following the last dose of study drug.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"96.4","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"93.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks after stopping study treatment, respectively.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"96.4","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"96.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"96.4","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"93.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure and Viral Relapse","description":"Virologic failure was defined as:\n\n* On-treatment virologic failure:\n\n  * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n  * Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n  * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)\n* Virologic relapse:\n\n  * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"3.6","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"3.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"3.6","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"3.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":59},"commonTop":["Asthenia","Headache","Cough","Fatigue","Pain"]}}}